Market Place
Sourcing Support
Quotient Sciences and Ensysce Biosciences Continue Collaboration PF614-MPAR-102
20 May 2024 //
PRESS RELEASE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
27 Feb 2024 //
ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
15 Feb 2024 //
ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
24 Oct 2023 //
ACCESSWIRE
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
18 Oct 2023 //
ACCESSWIRE
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
13 Oct 2023 //
ACCESSWIRE
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
08 Aug 2023 //
ACCESSWIRE
Ensysce Biosciences to Present its Overdose Protection Program at HEAL Meeting
14 Feb 2023 //
ACCESSWIRE
Ensysce Biosciences` PF614-MPAR Enters Final Stage of Phase 1 Study
25 Jan 2023 //
PRESS RELEASE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A
20 Dec 2022 //
ACCESSWIRE
Ensysce Biosciences begins patient dosing in second human abuse potential study
31 Oct 2022 //
PHARMABIZ
Ensysce Biosciences Announces Initiation of Second Human Abuse
22 Sep 2022 //
BIOSPACE
Ensysce & Quotient Announce a Partnership on the Testing of Ensysce`s PF614-MPAR
31 Aug 2022 //
PRESS LELEASE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Ensysce Bio Reports Fourth Quarter And Full Year 2021 Earnings Release Date
24 Mar 2022 //
PRESS RELEASE
Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference
23 Feb 2022 //
GLOBENEWSWIRE
Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
08 Feb 2022 //
GLOBENEWSWIRE
Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations
31 Jan 2022 //
GLOBENEWSWIRE
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
27 Jan 2022 //
GLOBENEWSWIRE
Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting
19 Jan 2022 //
GLOBENEWSWIRE
Ensysce Bio Achieves Successful Completion of Part A of MADBE Trial for PF614
04 Jan 2022 //
GLOBENEWSWIRE
Ensysce Biosciences Announces $15 Million Convertible Note Financing
27 Sep 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Announces $15 Million Convertible Note Financing
27 Sep 2021 //
GLOBENEWSWIRE
Recro acquires opioid addiction drug maker, will handle all FDA formalities
09 Sep 2021 //
ENDPTS
Ensysce Biosciences starts enrollment in early-stage PF614 study
08 Sep 2021 //
SEEKING ALPHA
Ensysce Enrolls First Cohort of Subjects in Next Generation Opioid, PF614 study
08 Sep 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Announces Notice of Allowance from the USPTO
05 Aug 2021 //
GLOBENEWSWIRE
Ensysce Bio Appointments David J. Kovacs VP Public Policy , David Tanzer
26 Jul 2021 //
GLOBENEWSWIRE
Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021
21 Jul 2021 //
GLOBENEWSWIRE
Ensysce Receives Notice of Award for Year Three of Multi-Year NIDA Grant
08 Jul 2021 //
GLOBENEWSWIRE
Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq
01 Jul 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Announces Closing of Merger
01 Jul 2021 //
BIOSPACE
Ensysce Biosciences Announces Closing of Merger
30 Jun 2021 //
GLOBENEWSWIRE
Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021
30 Jun 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Announces Closing of Merger
30 Jun 2021 //
BIOSPACE
Ensysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Phase 2
07 May 2021 //
GLOBENEWSWIRE
Ensysce Biosciences Receives Investigational New Drug Allowance
29 Apr 2021 //
GLOBENEWSWIRE
Ensysce Receives Investigational New Drug Allowance for its Unique PF614-MPAR
29 Apr 2021 //
BIOSPACE
Ensysce, a California Based Biotech With a Mission to Solve the Opioid Crisis
31 Dec 2020 //
BUSINESSWIRE
Ensysce, a California Based Biotech With a Mission to Solve the Opioid Crisis
31 Dec 2020 //
BUSINESSWIRE
